Balyasny Asset Management
KDNY

Balyasny Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Balyasny Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-78,400
Closed -$3.01M – 2878
2023
Q2 		$3.01M Buy
+78,400
New +$2.01M 0.01% 1236

Balyasny Asset Management's KDNY Position: Q3 2023 in Review

Balyasny Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 605,294 shares — an estimated $23.3M sold.

Balyasny Asset Management first reported a position in KDNY in Q1 2017 and held it in 6 quarters. The position peaked at $23.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Balyasny Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 605,294 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $23.3M.
  • Balyasny Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 6 quarters.
  • Balyasny Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $23.3M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Balyasny Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.